Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5CART in Relapsed and Refractory CD5+ Hematologic Cancer
NCT07234110Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2025
- Primary completion
- May 2027
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of Autologous CD5 CAR T-cells in hematologic cancer, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Safety and Maximum Tolerated Dose at 1 month. Started Sep 2025; status: recruiting.
02
Drugs
Autologous CD5 CAR T-cells
03
Conditions
hematologic cancer
Beyond the preview
Go deeper on NCT07234110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234110.